Irritability · children and adolescents with a diagnosis of autism
1 finding from 1 review
Hyperactivity (Child Behaviour Checklist Attention problems Subscale; lower = better) · children and adolescents with a diagnosis of autism
1 finding from 1 review
General health and function (Severity of Illness subscale of Clinical Global Impression Scale; lower = better) · children and adolescents with a diagnosis of autism
1 finding from 1 review
Social communication (Lethargy/Social withdrawal subscale of the ABC‐C; 0 to 64; lower = better) · children and adolescents with a diagnosis of autism
1 finding from 1 review
Stereotypical behaviours · children and adolescents with a diagnosis of autism
1 finding from 1 review
Side effects or other adverse events · children and adolescents with a diagnosis of autism
Galantamine plus risperidone may leads to higher adverse events (Side Effects Checklist) compared with placebo plus risperidone (low certainty).
1 finding from 1 review
Irritability · children and adolescents with a diagnosis of autism
1 finding from 1 review
Hyperactivity · children and adolescents with a diagnosis of autism
1 finding from 1 review
General health and function Not assessed · children and adolescents with a diagnosis of autism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall autism features (total score of RLRS; raw score means; lower = better) · children and adolescents with a diagnosis of autism
1 finding from 1 review
Social communication (Social Relationships subscale of RLRS; raw score means; lower = better) · children and adolescents with a diagnosis of autism
1 finding from 1 review
Clinical improvement D28b · people with mild/moderate/severe/critical COVID‐19
Tociliuzumab showed no clear difference in clinical improvement D28b compared with standard care/placebo (moderate certainty).
1 finding from 1 review
WHO progression score (level 7 or above) D28 · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether sarilumab changes WHO progression score (level 7 or above) D28 compared with standard care/placebo (very low certainty).
1 finding from 1 review
All‐cause mortality D28 · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether sarilumab changes all‐cause mortality D28 compared with standard care/placebo (very low certainty).
1 finding from 1 review
All‐cause mortality D60 or more · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether sarilumab changes all‐cause mortality D60 or more compared with standard care/placebo (very low certainty).
1 finding from 1 review
Adverse events ( · people with mild/moderate/severe/critical COVID‐19
Sarilumab showed no clear difference in adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
Sarilumab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review
Clinical improvement D28b · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether clazakizumab changes clinical improvement D28b compared with standard care/placebo (very low certainty).
1 finding from 1 review
Clinical improvement D60 or above · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether clazakizumab changes clinical improvement D60 or more compared with standard care/placebo (very low certainty).
1 finding from 1 review
WHO progression score (level 7 or above) D28 · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether clazakizumab changes WHO progression score (level 7 or above) D28 compared with standard care/placebo (very low certainty).
1 finding from 1 review